Sumitomo Dainippon Pharma Co Ltd (4506.T)
13 Dec 2019
Dec 5 Privately held drug developer Enzyvant said on Thursday the U.S. Food and Drug Administration declined to approve its regenerative tissue therapy for a rare immunodeficiency disorder and raised concerns about its manufacturing.
TOKYO, Nov 25 Japanese stocks rose by the most in two weeks on Monday as investors turned more confident the United States and China could reach an agreement to de-escalate their trade war.
TOKYO, Nov 25 Japanese stocks rose on Monday by the most in three weeks as investors turned optimistic about the chance that the United States and China will reach an agreement to de-escalate their trade war.
TOKYO, Nov 20 Japanese shares fell on Wednesday on worries over the progress of trade talks between Washington and Beijing, with the information technology sector recording the biggest decline led by falls in semiconductor companies.
TOKYO, Nov 20 Japanese shares fell on Wednesday after U.S. President Donald Trump said he would raise tariffs on Chinese imports if no deal was reached with Beijing to end a trade war.
TOKYO, Oct 29 Japanese stocks rose to the highest in more than a year on Tuesday, as negotiators from the United States and China moved a step closer to scaling back their bruising trade war in a boost to the prospects for corporate earnings.
TOKYO, Oct 29 Japan's Nikkei index rose to the highest in more than a year on Tuesday as optimism that the United States and China can scale back their bruising trade war buoyed hopes for higher corporate earnings.
Sept 6 The following bids, mergers, acquisitions and disposals were reported by 2000 GMT on Friday:
TOKYO Japan's Sumitomo Dainippon Pharma Co will pay $3 billion for a 10% stake in Swiss drugmaker Roivant Sciences Ltd and interests in five of its biopharmaceutical businesses, the two companies said on Friday.
|Konjunktur abhängige Waren & Dienstleistungen||+0.62%|
|Konjunktur unabhängige Waren & Dienstleistungen||+0.21%|
Nachrichten aus der Wirtschaft
Paris/Wien Frankreichs Notenbank-Chef Francois Villeroy de Galhau erwartet vorerst keine neuen geldpolitischen Schritte der Europäischen Zentralbank (EZB).